Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
A concise overview of proven techniques to implement and maintain a zero based budget with measurable outcomes.
18,361 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
As the Fed's path becomes less predictable, investors weigh how many rate cuts to expect in 2026. This guide breaks d...
BlackRock’s chief executive argues that AI’s biggest impact is on who owns wealth, not just who loses a job. Here’s h...
A new class of job-search firms charges up front fees to run an entire hunt for candidates. The market that reverse r...
Curious about whether Blue Owl Capital can outperform the market? This guide breaks down what to watch, how to analyz...
NVIDIA stunned markets with a trillion-dollar order pipeline, but the stock hardly moved. This piece explains what th...
Oil tensions linked to Iran have put pressure on stocks, lifting energy prices and weighing on the S&P 500 and Nasdaq...
Bitcoin breached the $80,000 mark, but market watchers say the rally is not backed by solid demand. The bitcoin marke...
The FDA approved two fruit-flavored vape lines from a Los Angeles company, a notable policy reversal that comes as po...
When mortgage markets swung on interest-rate headlines, one fund pressed deeper into PennyMac. This article explains ...
For investors who can stomach big swings, choosing between XRP and Hyperliquid isn’t simple. This guide breaks down r...
Amazon’s cash flow story isn’t simple. This guide breaks down what drives cash in and out, what to expect in 2026, an...